FREMONT, Calif., Feb. 3 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. , a leading developer of state-of-the-art genetic analysis systems, today announced that WaferGen scientists will present validation results of the company's SmartChip(TM) Real-Time PCR System at Cambridge Healthcare Institute's 17th International Molecular Medicine Tri-Conference. The conference is being held from February 3-5, 2010 at the Moscone North Convention Center in San Francisco.
Title: "Performance of the SmartChip System from WaferGen"
Summary: An overview of the company's novel whole genome, high-throughput SmartChip Real-Time PCR System, and data to demonstrate the system's ability to quantify gene expression levels by real-time PCR for a large number of genes at one time utilizing a simple workflow.
WaferGen Biosystems, Inc. is an emerging leader in the development, manufacture and sale of state-of-the-art systems for genetic analysis for the life science and pharmaceutical industries. The company recently launched its new innovative fee-based service for gene-expression profiling while continuing to actively develop its SmartChip Real-Time PCR System that is designed as the first whole genome, high-throughput gene expression real-time PCR platform. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker discovery and validation. For additional information, please see http://www.wafergen.com.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2008 and the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. Investors and security holders are urged to read this document free of charge on the SEC's web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
WaferGen Biosystems, Inc.